BeiGene
BGNE
#968
Rank
NZ$35.44 B
Marketcap
$320.89
Share price
2.21%
Change (1 day)
15.42%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Net assets

Net assets on the balance sheet as of September 2024 : NZ$6.07 Billion

According to BeiGene 's latest financial reports the company has NZ$6.07 Billion in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

BeiGene - Net assets on balance sheet (from 2014 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$NZ$5.59 B-18.98%
2022-12-31$NZ$6.90 B-23.1%
2021-12-31$NZ$8.97 B67.43%
2020-12-31$NZ$5.36 B269.14%
2019-12-31$NZ$1.45 B-44.43%
2018-12-31$NZ$2.61 B171.36%
2017-12-31$NZ$0.96 B89.1%
2016-12-31$NZ$0.50 B369.18%
2015-12-31$NZ$0.10 B230.18%
2014-12-31$NZ$32.88 M-169.79%
2013-12-31$-NZ$47.13 Million

Net assets for similar companies or competitors

Company Net assets differencediff. Country
NZ$10.62 M-99.82%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$2.47 B-59.16%๐Ÿ‡บ๐Ÿ‡ธ USA